Major depressive disorder (MDD) is a debilitating psychiatric condition characterized by a persistently low mood, a lack of ...

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...

Experts predict a test measuring p-tau217 in blood plasma may become a standard screening tool for Alzheimer’s disease in ...

A Macquarie University–led study has identified coordinated abnormalities in cellular energy, immune function and blood ...

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...

The use of blood tests, particularly of p-tau217, in the diagnosis of Alzheimer’s disease has taken off in the last few years, with the number of tests being prescribed now doubling every four to six ...

CervoMed Inc. (NASDAQ:CRVO) on Monday shared 32-week data from the Extension phase of its Phase 2b RewinD-LB trial evaluating oral neflamapimod in patients with Dementia with Lewy Bodies (DLB). The ...

What if a simple blood sample could tell us how patients might respond to immunotherapy? Join us for this 30-minute multiomics coffee break and discover how researchers from The ACRF Spatial Immune ...

Plasma p-tau217 successfully identified Alzheimer's pathology in several neurodegenerative syndromes. This included disorders not typically associated with Alzheimer's disease, like frontotemporal ...

Studies on the relationships between diseases of the urinary system and human plasma proteomes have identified several potential biomarkers. However, none of these studies have elucidated the causal ...

The BD P800™ Blood Collection System stands at the forefront of metabolic research, particularly in the context of obesity. Its unique ability to stabilize critical plasma markers has revolutionized ...